21 CFR 211.192 batch review and investigation requirements
21 CFR 211.192 requires quality unit approval of records before batch release and thorough investigation of discrepancies or specification failures.
21 CFR 211.192 requires quality control unit review and approval of all drug product production and control records before batch release or distribution. It also requires thorough investigation of unexplained discrepancies or specification failures, even after distribution, with written conclusions and followup. Both duties appear in the section titled "Production record review."
For pharmaceutical quality teams, the scope goes beyond laboratory out-of-specification (OOS) results. Packaging and labeling records belong in the review, and a discrepancy can require investigation without a failed laboratory test. Section 211.192 sets out both obligations.
What 21 CFR 211.192 requires
The quality control unit must review all drug product production and control records, including packaging and labeling records. Its review determines compliance with established, approved written procedures. Review and approval must happen before the batch is released or distributed. A review limited to laboratory results would not cover the records named in the rule.
The investigation requirement has two triggers: any unexplained discrepancy, or failure of a batch or any of its components to meet any specification. This includes theoretical-yield discrepancies against the maximum or minimum percentages established in master production and control records. Use those established bounds. Section 211.192 sets no universal numerical yield limit.
The investigation duty applies "whether or not the batch has already been distributed." It does not depend on first proving a manufacturing root cause. An unexplained discrepancy or specification failure is itself a trigger under § 211.192.
Investigation scope must reach other batches of the same drug product and other drug products potentially associated with the failure or discrepancy. It does not automatically cover every unrelated batch at the site. The rule also requires a written investigation record containing "the conclusions and followup."
How to organize production record review and investigation
A useful working checklist separates the records reviewed from the problem investigated. The following is an organizing aid, not an FDA-prescribed form. It maps to the review, scope and documentation duties in § 211.192.
| Working item | What to capture |
|---|---|
| Records reviewed | Identify the production and control records, including packaging and labeling records. |
| Procedure compliance | Record the review against established, approved written procedures. |
| Investigation trigger | Describe the unexplained discrepancy or the specification that the batch or component failed. |
| Associated batches and products | Document the scope considered and explain which batches or products may be associated with the problem. |
| Conclusions and followup | State the investigation's conclusions and record the followup. |
| Quality unit approval | Make the required review and approval before release or distribution clear in the record. |
Keep the specific trigger visible as the investigation develops. For a yield discrepancy, for example, record the applicable established bounds rather than calling the result merely "low." For an associated-batch review, explain the connection to the discrepancy instead of adding unrelated batches without a reason. These are practical ways to make the rule's requirements traceable in the record.
Do not treat investigation closure as a substitute for production record review and approval. Section 211.192 requires both. It is not a complete batch-release decision tree. Assess disposition under all applicable requirements and relevant FDA guidance.
Where OOS investigations fit
FDA describes OOS results as results outside specifications or acceptance criteria established in applications, drug master files, official compendia or by manufacturers. Its scope includes in-process laboratory tests outside established specifications. See FDA's guidance on investigating OOS test results for pharmaceutical production.
OOS investigations are therefore one application of the broader § 211.192 duty. They do not replace investigations of unexplained production discrepancies. Keep the CFR requirement separate from FDA's guidance: the regulation states the legal duties, while the guidance addresses OOS investigation practice. Consult the FDA guidance for detailed OOS procedures rather than treating this section as a retesting protocol.
Related requirements for quality teams
Several neighboring sections help place production record review in context. They address different tasks, so none replaces the review and investigation obligations above.
- 21 CFR 211.22 sets quality control unit authority and responsibilities. These include reviewing production records to assure that errors have not occurred or have been fully investigated.
- 21 CFR 211.84 covers incoming components, containers and closures. Lots must remain withheld from use until appropriately sampled, tested or examined, and released by the quality control unit. Lots that fail applicable specifications must be rejected.
- 21 CFR 211.100 requires written production and process procedures. Performance must be documented when it occurs, and deviations must be recorded and justified.
- 21 CFR 211.166 requires a written stability-testing program. A stability specification failure is relevant to the broader investigation duty; stability testing does not replace batch record review.
Does the section set an investigation deadline?
Section 211.192 sets no numerical investigation completion deadline, fixed retest count or particular CAPA template. That does not remove other applicable obligations, reporting deadlines or requirements in the firm's procedures. Check those separately rather than assigning a deadline that this section does not contain.
RegAffairs AI's answer on failed drug batches and investigation requirements links to the stored regulatory sources.